DAWN Key Statistics, Chart & Performance
The current stock price of DAWN is 9.385 USD. In the past month the price increased by 0.43%. In the past year, price decreased by -26.57%.
DAWN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.45 | 408.31B | ||
| AMGN | AMGEN INC | 15.11 | 177.98B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.38 | 116.20B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.3 | 81.85B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.57 | 52.52B | ||
| INSM | INSMED INC | N/A | 37.79B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 10.57 | 25.97B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.03 | 21.63B | ||
| INCY | INCYTE CORP | 15.31 | 19.29B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About DAWN
Company Profile
Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in Brisbane California, California and currently employs 184 full-time employees. The company went IPO on 2021-05-27. The firm partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. The Company’s commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases. Its pipeline product candidates include DAY301 and VRK1 program. The DAY301 candidate is a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody (mAb), conjugated with a topoisomerase I inhibitor through a stable and hydrophilic modified valine-alanine (VA) cleavable linker. Its VRK1 program is a novel target involved in the regulation of cell division and DNA damage repair.
Company Info
DAY ONE BIOPHARMACEUTICALS I
1800 Sierra Point Parkway, Suite 200
Brisbane California CALIFORNIA US
CEO: Jeremy Bender
Employees: 184
Phone: 16504840899
DAY ONE BIOPHARMACEUTICALS I / DAWN FAQ
What does DAWN do?
Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in Brisbane California, California and currently employs 184 full-time employees. The company went IPO on 2021-05-27. The firm partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. The Company’s commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases. Its pipeline product candidates include DAY301 and VRK1 program. The DAY301 candidate is a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody (mAb), conjugated with a topoisomerase I inhibitor through a stable and hydrophilic modified valine-alanine (VA) cleavable linker. Its VRK1 program is a novel target involved in the regulation of cell division and DNA damage repair.
Can you provide the latest stock price for DAY ONE BIOPHARMACEUTICALS I?
The current stock price of DAWN is 9.385 USD. The price decreased by -0.69% in the last trading session.
Does DAWN stock pay dividends?
DAWN does not pay a dividend.
How is the ChartMill rating for DAY ONE BIOPHARMACEUTICALS I?
DAWN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the market expecting DAWN stock to perform?
15 analysts have analysed DAWN and the average price target is 22.7 USD. This implies a price increase of 141.82% is expected in the next year compared to the current price of 9.385.
Can you provide the growth outlook for DAY ONE BIOPHARMACEUTICALS I?
The Revenue of DAY ONE BIOPHARMACEUTICALS I (DAWN) is expected to grow by 21.23% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is DAY ONE BIOPHARMACEUTICALS I worth?
DAY ONE BIOPHARMACEUTICALS I (DAWN) has a market capitalization of 963.65M USD. This makes DAWN a Small Cap stock.
DAWN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to DAWN. When comparing the yearly performance of all stocks, DAWN turns out to be only a medium performer in the overall market: it outperformed 60.95% of all stocks.
DAWN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to DAWN. While DAWN has a great health rating, there are worries on its profitability.
DAWN Financial Highlights
Over the last trailing twelve months DAWN reported a non-GAAP Earnings per Share(EPS) of -1.47. The EPS increased by 17.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.54% | ||
| ROE | -33.66% | ||
| Debt/Equity | 0 |
DAWN Forecast & Estimates
15 analysts have analysed DAWN and the average price target is 22.7 USD. This implies a price increase of 141.82% is expected in the next year compared to the current price of 9.385.
For the next year, analysts expect an EPS growth of 41.61% and a revenue growth 21.23% for DAWN